Welcome to Jianke online pharmacy! Sign in Free registration
reminder:The pictures are the real photos of the original products taken by Jianke for reference only; In case of new packaging listing, there may be update lag, please take the physical object as the standard!
Baidu certification

Travoprost eye drops (sulvestan)

Reduce the elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, who are intolerant or ineffective to the use of other intraocular pressure reducing drugs (they can't achieve the goal after repeated use). More role
App download minus 10 yuan
Common name:
Travoprost eye drops
Product No.:
C14200220498
Approval No.:
H20181024 (original h20130813) (inquired by the State Drug Administration)
Jianke price:
¥235.69
Product specification:
2.5ml:0.1mg
Manufacturer:
Alcon CUSI, S.A. (Spain)
number        Quantity:
Add to list
Tips:
This product is a prescription drug. Please buy it with the prescription paper; Delivered by Jianke offline drugstore
 
(for assistance, please call400-086-5111
Jianke promises:
Genuine guarantee
Bank remittance / transfer online payment
  • Product introduction
  • instructions
  • Qualification certificate
  • Relevant information
Product name Travoprost eye drops (sulvestan)
Main raw materials Travoprost.
Main role Reduce the elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, who are intolerant or ineffective to the use of other intraocular pressure reducing drugs (they can't achieve the goal after repeated use).
Product specification 2.5ml:0.1mg
Usage and dosage The recommended dosage is 1 drop per night into the affected eye. The dose should not exceed once a day, because frequent use will reduce the intraocular pressure lowering effect of the drug. The IOP lowering effect of sulvetin began to appear about 2 hours after administration, and reached the maximum at 12 hours. Sulvestan can be used with other topical drugs to reduce intraocular pressure. When more than one ophthalmic drug is used at the same time, the dropping time of each drug shall be at least 5 minutes apart.
manufacturing enterprise Alcon CUSI, S.A. (Spain)
Jianke commitment
  • Genuine guarantee, formal invoice

    Jianke.com is an approved (B2C) Internet drug legitimate business enterprise in Guangdong Province. It signs a direct supply agreement with the manufacturer and can issue formal invoices for the purchased goods.

  • Private packaging, privacy protection

    When jianke.com packages and delivers goods, the appearance of the packing box only displays the necessary information for delivery, and the name of the purchased goods will not appear. The specific shopping list is in the package to protect the privacy of customers.

  • Efficient logistics and safe arrival

    All products of jianke.com adopt the door-to-door distribution mode of third-party logistics. They are delivered to the nearest warehouse according to your distribution address, so as to deliver them to you on time.

  • Three warehouses to ensure inventory

    Jianke.com has three warehouses in Guangzhou, Dongguan and Wuhan, equipped with first-class equipment, constant temperature and humidity to ensure drug quality. Specially assigned person to manage and ensure product inventory.

[drug name] Travoprost eye drops (sulvestan)

[common name] Travoprost eye drops

[specification and model] 2.5ml:0.1mg

[manufacturer] Alcon CUSI, S.A. (Spain)

[drug type] Western medicine

[approval No.] H20181024 (original h20130813)

[validity period] 24 months

[functional indications] Reduce the elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, who are intolerant or ineffective to the use of other intraocular pressure reducing drugs (they can't achieve the goal after repeated use).

[usage and dosage] The recommended dosage is 1 drop per night into the affected eye. The dose should not exceed once a day, because frequent use will reduce the intraocular pressure lowering effect of the drug. The IOP lowering effect of sulvetin began to appear about 2 hours after administration, and reached the maximum at 12 hours. Sulvestan can be used with other topical drugs to reduce intraocular pressure. When more than one ophthalmic drug is used at the same time, the dropping time of each drug shall be at least 5 minutes apart.

[adverse reactions] Adverse reactions were classified according to the following conventions: very common (≥ 1 / 10), common (≥ 1 / 100 to < 1 / 10), uncommon (≥ 1 / 1000 to < 1 / 100), rare (≥ 1 / 10000 to < 1 / 1000), very rare (< 1 / 10000) or unknown (the incidence cannot be evaluated based on known data). In each frequency group, adverse reactions were ranked in descending order of severity. Adverse reactions were obtained from the data of sulvestan clinical study and post marketing study. [see the instructions for others].

[precautions] This product may gradually cause eye color change by increasing the number of melanosomes (pigment particles) in iris melanocytes. Before treatment, patients should be informed of possible permanent changes in eye color. Monocular treatment can lead to permanent heterochromatism. The long-term effects and consequences on melanocytes are unclear. The change of iris color in patients occurs slowly and may not be easy to detect for months to years. Eye color changes were mainly seen in patients with multi pigmented iris, such as marked blue, marked gray, marked yellow and brown green; However, this change also occurs in patients with brown eyes. Brown pigment is typically distributed from around the pupil to the periphery of the affected eye, but the brown of the whole or part of the iris may become darker. No further increase of brown iris pigment was observed after termination of treatment. Periorbital and eye face changes In a controlled clinical trial, it was reported that 0.4% of patients using this product had darkened periorbital and / or eyelid skin. Prostaglandin analogues can also cause changes around the orbit and eyelids, including deepening of the eyelid sulcus. Incoming products may gradually change the eyelashes of the treated eyes; These changes were observed in about half of the patients in the clinical trial, including longer and denser eyelashes, pigmentation, and / or an increase in the number of eyelashes. The mechanism and long-term results of changing eyelashes are unclear. It was shown in the work substance test that travoprost could cause the mild expansion of pie's facial fissure, but this phenomenon has not been observed in the human test. It is speculated that it may be species-specific. No experience in using this product for inflammatory eye conditions; This product has not been evaluated for the treatment of neovascular, angle closure, narrow atrial angle or congenital glaucoma. At the same time, there is limited experience in the treatment of open-angle glaucoma with thyroid ophthalmopathy, intraocular lens, pigmented or pseudoexfoliative syndrome. Therefore, sulvestan should be used with caution in patients with active inner eye inflammation. [see the instructions for others].

[taboo] It is forbidden for those who are allergic to the active ingredients or any excipients of this product.

[listing Permit Holder] ALCONCusi,S.A.

[packaging unit] box

[main ingredients] Travoprost.

[character] This product is colorless to light yellow clear liquid.

[applicable population] adult

[medication for pregnant and lactating women] Women of childbearing age should not use this product unless adequate contraceptive measures are taken (see [pharmacology and toxicology]) Travoprost has harmful pharmacological effects on pregnant women and / or fetuses / newborns. Pregnant women should not use this product unless it is clearly necessary. lactation It is unclear whether travoprost from eye drops is secreted in milk. Animal experiments show that travoprost and its metabolites are secreted in milk sweat. This product is not recommended for lactating women. birth There is no data on the impact of sulvestan on human fertility. Animal studies have shown that travoprost has no effect on fertility when administered at a dose 250 times higher than the maximum recommended human eye dose.

[medication for children] The safety and efficacy of sulvestan in children have not been established. No data available.

[medication for elderly patients] There was no significant difference in efficacy and adverse reactions between elderly patients and adult patients.

[storage] Shading, sealed storage.

Praise degree

zero%

    reminder

    Dear customer:

    In case of emergency, please call the ordering hotline400-086-5111Consult a health care professional pharmacist.

    Travoprost eye drops (sulvestan)

    ¥235.69

    reminder

    To ensure your privacy, please enter the verification code and click "confirm callback". Our customer service staff will call back the phone number you entered later!

    Please enter the correct verification code!
    Loding...
    Can't see clearly. Change one

    Dear customer:

    Your callback failed this time. Please re-enter the verification code to try. Thank you!